# OnCo record trusight-oncology-comprehensive (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/trusight-oncology-comprehensive/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "trusight-oncology-comprehensive" ;
  schema:name "TruSight Oncology Comprehensive"@en ;
  schema:description "A large gene panel hospitals can run themselves, approved by the FDA in 2024 as a companion diagnostic for the tumour-agnostic drug larotrectinib."@en ;
  schema:url <https://onco.cc/drugs/trusight-oncology-comprehensive/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://www.illumina.com/products/by-type/clinical-research-products/> ;
  onco:status "approved" ;
  onco:tag "test" ;
  onco:modality "Distributable tissue NGS companion diagnostic test (500+ genes, DNA and RNA)" ;
  schema:alternateName "TSO Comprehensive" ;
  onco:approval "EU 2022: CE-IVD comprehensive genomic profiling", "US 2024: Companion diagnostic for larotrectinib (NTRK fusions) with tumour-profiling claims" ;
  onco:cancers <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/colorectal/> ;
  onco:technologies <https://onco.cc/technologies/cgp/>, <https://onco.cc/technologies/companion-diagnostic/> ;
  onco:targets <https://onco.cc/targets/ntrk/> ;
  onco:drugs <https://onco.cc/drugs/larotrectinib/> ;
  onco:companies <https://onco.cc/companies/illumina/> ;
  onco:terms <https://onco.cc/terms/ngs/>, <https://onco.cc/terms/tmb/>, <https://onco.cc/terms/msi/> .